Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
541
-
542
-
543
-
544
-
545
-
546
-
547
Measurements of the amount of ATP released by bladder distention and VNUT expression in the bladder.
Published 2024Subjects: -
548
-
549
KO of iPLA<sub>2</sub>γ attenuates development of albuminuria in STZ-induced diabetic nephropathy.
Published 2024Subjects: -
550
-
551
Control (Ctrl) GECs are more susceptible to injury compared to iPLA<sub>2</sub>γ KO GECs.
Published 2024Subjects: -
552
-
553
Podocyte numbers in control and iPLA<sub>2</sub>γ KO mice (WT1-positive cells).
Published 2024Subjects: -
554
-
555
-
556
Presentation 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
557
Table 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signall...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
558
Changes in best-corrected visual acuity and total area reduction ratio of the epiretinal membrane (ERM) during follow-up.
Published 2025“…<p>(a) During the follow-up period, the stable group showed no significant change in visual acuity, whereas the progression group exhibited a decrease compared to baseline starting at 12 months, with greater changes than those in the stable group beginning at 6 months. …”
-
559
Data.
Published 2025“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”
-
560
Baseline characteristics of patients.
Published 2025“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”